BENNETT C FRANK 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) EVP Bennett C. Frank Sells 5,885 Shares
What Happened
Bennett C. Frank, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), had 11,421 shares report as acquired on 2026-01-29 due to the vesting of performance-based restricted stock units (PRSUs). On 2026-01-30 he sold 5,885 of those shares in open-market transactions for a weighted average price of $82.95, generating proceeds of approximately $488,141. The initial acquisition (listed at $0.00) reflects the vesting of PRSUs, not a cash purchase.
Key Details
- Transaction dates: 2026-01-29 (award/vesting) and 2026-01-30 (open-market sale). Filing date: 2026-02-02 (Form 4).
- Sale: 5,885 shares sold; weighted average price $82.95; total proceeds ≈ $488,141. Reported sale price range: $82.94–$82.95.
- Award: 11,421 shares reported acquired on vesting at $0.00 (these were PRSUs).
- Shares owned after the transactions: not specified in the provided filing.
- Filing timeliness: Form 4 filed 2026-02-02; the filing covers the Jan 29–30 events and was submitted within the standard reporting window.
Context
- Footnote on the award: The 11,421 shares were PRSUs tied to a performance period (grant reported Jan 18, 2023). The Compensation Committee certified relative total shareholder return vs. peers at a level that produced a payout of 167.27% of target (PRSUs can pay 0%–200% of target).
- Footnote on the sale: The $82.95 price is a weighted average; the shares were sold in multiple transactions at prices between $82.94 and $82.95. The filer offers to provide breakdowns of amounts sold at each separate price upon request.
- Interpretation: The filing shows a routine disposition of vested equity rather than a new purchase; it is factual reporting of vesting and an open-market sale and does not, by itself, indicate management’s forward-looking view.
Insider Transaction Report
Form 4
BENNETT C FRANK
EVP, Chief Scientific Officer
Transactions
- Award
Common Stock
[F1]2026-01-29+11,421→ 106,178 total - Sale
Common Stock
[F2]2026-01-30$82.95/sh−5,885$488,141→ 100,293 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.94 to $82.95 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Signature
By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett|2026-02-02